Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. / Møller, S; Becker, U; Grønbaek, M; Juul, A; Winkler, K; Skakkebaek, N E.

In: Journal of Hepatology, Vol. 21, No. 5, 1994, p. 710-7.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Møller, S, Becker, U, Grønbaek, M, Juul, A, Winkler, K & Skakkebaek, NE 1994, 'Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis', Journal of Hepatology, vol. 21, no. 5, pp. 710-7.

APA

Møller, S., Becker, U., Grønbaek, M., Juul, A., Winkler, K., & Skakkebaek, N. E. (1994). Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. Journal of Hepatology, 21(5), 710-7.

Vancouver

Møller S, Becker U, Grønbaek M, Juul A, Winkler K, Skakkebaek NE. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. Journal of Hepatology. 1994;21(5):710-7.

Author

Møller, S ; Becker, U ; Grønbaek, M ; Juul, A ; Winkler, K ; Skakkebaek, N E. / Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. In: Journal of Hepatology. 1994 ; Vol. 21, No. 5. pp. 710-7.

Bibtex

@article{47c2cfe94ec54b16a1b5aab4a0b27173,
title = "Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis",
abstract = "As growth hormone possesses anabolic properties that are active on protein metabolism, and thus of potential benefit to patients with chronic liver disease, we determined the metabolic effects of recombinant human growth hormone on insulin-like growth factor-I (IGF-I) its specific binding proteins, and liver function. Twenty consecutive patients with cirrhosis were randomized to recombinant human growth hormone (Norditropin, 4 I.U. twice daily) subcutaneously for 6 weeks (n = 10) or conventional medical treatment (n = 10). The serum concentrations of insulin-like growth factor-I in the recombinant human growth hormone group increased after 3 (p <0.01) and 6 weeks (p <0.02), whereas no significant changes were observed in the control group. The change in insulin-like growth factor-I during the treatment period was expressed as area under the curve (AUC). The AUCIGF-I was significantly larger in the recombinant human growth hormone group (median AUCIGF-I: 12.1, range: 0.0-54.7 weeks.nmol/l) than in the control group (median AUCIGF-I: 0.2, range: -10.6-9.9 weeks.nmol/l) (p <0.007). Insulin-like growth factor binding protein-3 concentrations increased in the recombinant human growth hormone treated patients as well as in controls, whereas no change in insulin-like growth factor binding protein-1 concentrations was found. No significant changes were seen in the area under the curve for biochemical liver function tests. We conclude that administration of recombinant human growth hormone induces an increase in very low levels of insulin-like growth factor-I, even in patients with cirrhosis with advanced disease, but the clinical benefits remain to be demonstrated.",
author = "S M{\o}ller and U Becker and M Gr{\o}nbaek and A Juul and K Winkler and Skakkebaek, {N E}",
year = "1994",
language = "English",
volume = "21",
pages = "710--7",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis

AU - Møller, S

AU - Becker, U

AU - Grønbaek, M

AU - Juul, A

AU - Winkler, K

AU - Skakkebaek, N E

PY - 1994

Y1 - 1994

N2 - As growth hormone possesses anabolic properties that are active on protein metabolism, and thus of potential benefit to patients with chronic liver disease, we determined the metabolic effects of recombinant human growth hormone on insulin-like growth factor-I (IGF-I) its specific binding proteins, and liver function. Twenty consecutive patients with cirrhosis were randomized to recombinant human growth hormone (Norditropin, 4 I.U. twice daily) subcutaneously for 6 weeks (n = 10) or conventional medical treatment (n = 10). The serum concentrations of insulin-like growth factor-I in the recombinant human growth hormone group increased after 3 (p <0.01) and 6 weeks (p <0.02), whereas no significant changes were observed in the control group. The change in insulin-like growth factor-I during the treatment period was expressed as area under the curve (AUC). The AUCIGF-I was significantly larger in the recombinant human growth hormone group (median AUCIGF-I: 12.1, range: 0.0-54.7 weeks.nmol/l) than in the control group (median AUCIGF-I: 0.2, range: -10.6-9.9 weeks.nmol/l) (p <0.007). Insulin-like growth factor binding protein-3 concentrations increased in the recombinant human growth hormone treated patients as well as in controls, whereas no change in insulin-like growth factor binding protein-1 concentrations was found. No significant changes were seen in the area under the curve for biochemical liver function tests. We conclude that administration of recombinant human growth hormone induces an increase in very low levels of insulin-like growth factor-I, even in patients with cirrhosis with advanced disease, but the clinical benefits remain to be demonstrated.

AB - As growth hormone possesses anabolic properties that are active on protein metabolism, and thus of potential benefit to patients with chronic liver disease, we determined the metabolic effects of recombinant human growth hormone on insulin-like growth factor-I (IGF-I) its specific binding proteins, and liver function. Twenty consecutive patients with cirrhosis were randomized to recombinant human growth hormone (Norditropin, 4 I.U. twice daily) subcutaneously for 6 weeks (n = 10) or conventional medical treatment (n = 10). The serum concentrations of insulin-like growth factor-I in the recombinant human growth hormone group increased after 3 (p <0.01) and 6 weeks (p <0.02), whereas no significant changes were observed in the control group. The change in insulin-like growth factor-I during the treatment period was expressed as area under the curve (AUC). The AUCIGF-I was significantly larger in the recombinant human growth hormone group (median AUCIGF-I: 12.1, range: 0.0-54.7 weeks.nmol/l) than in the control group (median AUCIGF-I: 0.2, range: -10.6-9.9 weeks.nmol/l) (p <0.007). Insulin-like growth factor binding protein-3 concentrations increased in the recombinant human growth hormone treated patients as well as in controls, whereas no change in insulin-like growth factor binding protein-1 concentrations was found. No significant changes were seen in the area under the curve for biochemical liver function tests. We conclude that administration of recombinant human growth hormone induces an increase in very low levels of insulin-like growth factor-I, even in patients with cirrhosis with advanced disease, but the clinical benefits remain to be demonstrated.

M3 - Journal article

VL - 21

SP - 710

EP - 717

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -

ID: 48486846